AstraZeneca PLC (NASDAQ:AZN) Q2 2024 Earnings Conference Call July 25, 2024 6:45 AM ET
Company Participants
Andy Barnett - Head, IR
Pascal Soriot - Executive Director & CEO
Aradhana Sarin - Executive Director & CFO
David Fredrickson - EVP, Oncology Business
Susan Galbraith - EVP, Oncology Research and Development
Ruud Dobber - EVP & President, BioPharmaceuticals
Sharon Barr - EVP, BioPharmaceuticals Research and Development
Marc Dunoyer - CEO, Alexion and Chief Strategy Officer, AstraZeneca
Dave Fredrickson - EVP, Oncology Business
Leon Wang - EVP, International and President, China
Conference Call Participants
Mark Purcell - Morgan Stanley
James Gordon - JPMorgan
Gonzalo Artiach - Danske Bank
Rajan Sharma - Goldman Sachs
Sachin Jain - Bank of America Merrill Lynch
Tim Anderson - Wolfe
Emmanuel Papadakis - Deutsche Bank
Peter Welford - Jefferies
Seamus Fernandez - Analyst
Matthew Weston - UBS
Mattias Haggblom - Handelsbanken
Pete Verdult - Citi
Luisa Hector - Berenberg Capital Markets
Operator
Welcome to AstraZeneca's Half Year and Q2 Results 2024 Webinar for Investors and Analysts.
Before I hand over to AstraZeneca, I'd like to read the safe harbor statement. The company intends to utilize the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca. Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
Any forward-looking statements made on this call reflect the knowledge and information available at the time of this call. The company undertakes no obligation to update forward-looking statements. Please also carefully review the forward-looking statements disclaimer in the slide deck that accompanies this presentation. [Operator instructions] And with that, I would now like to hand the conference over to the company.
Andy Barnett
A warm welcome to AstraZeneca's half-year and second-quarter 2024 presentation conference call and webcast for investors and analysts. I'm Andy Barnett, head of investor relations. And before I hand over to Pascal and other members of our executive team, I would like to cover some important housekeeping points. Firstly, all the materials presented today as additional and additional resources including updated epidemiology tables and our recent Investor Day materials are available on our Investor Relations website.